|
|
||||||||
Original Research Communication |
1 From Clinical Mass Spectrometry, Childrens Hospital Medical Center, Cincinnati (KDRS, LZ-N, NMB, BEW, and WTB); the School of Biomedical and Life Sciences, University of Surrey, Guildford, United Kingdom (MSF, TA, and AC); the College of Pharmacy, University of Cincinnati College of Medicine (PD); and the University of St Andrews, School of Chemistry, St Andrews, Fife, United Kingdom (MFO and NPB).
Background: Despite significant interest in the risks and benefits of phytoestrogens to human health, few data exist on their pharmacokinetics in humans.
Objective: We investigated the pharmacokinetics of the 13C isotopic forms of daidzein and genistein in healthy humans, specifically addressing intraindividual variability, effect of increasing intake, and influence of prolonged exposure to a soy food diet.
Design: Premenopausal women (n = 16) were administered 0.4 mg [13C]daidzein or [13C]genistein/kg body wt orally on 3 occasions, including once after eating soy foods for 7 d. On a further occasion the dose was doubled. Plasma and urinary [13C]isoflavone concentrations were measured by mass spectrometry.
Results: Serum concentrations of [13C]genistein and [13C]daidzein peaked after 5.5 and 7.4 h, respectively. The systemic bioavailability and maximum serum concentration of [13C]genistein were significantly greater than those of [13C]daidzein. The bioavailability of both isoflavones did not increase linearly when the dietary intake was doubled. The mean volume of distribution normalized to bioavailability (Vd/F), clearance rate, and half-life of [13C]daidzein were 336.25 L, 30.09 L/h, and 7.75 h, respectively; the corresponding values for [13C]genistein were 258.76 L, 21.85 L/h, and 7.77 h. The average recovery of [13C]daidzein and [13C]genistein in urine was 30.1% and 9.0% of the dose ingested, respectively.
Conclusions: The serum pharmacokinetics of [13C]daidzein and [13C]genistein were reproducible among healthy women, and genistein was more bioavailable than was daidzein. Pharmacokinetics were unaffected by chronic exposure to soy foods. Urinary isoflavone concentrations correlated poorly with maximal serum concentrations, indicating the limitations of urine measurements as a predictor of systemic bioavailability. The bioavailability of both isoflavones was nonlinear at higher intakes, suggesting that uptake is rate-limiting and saturable.
Key Words: Isoflavones pharmacokinetics stable isotopes bioavailability absorption metabolism women phytoestrogens daidzein genistein soy foods
This article has been cited by other articles:
![]() |
K. D. R. Setchell, X. Zhao, S. E. Shoaf, and K. Ragland The Pharmacokinetics of S-(-)Equol Administered as SE5-OH Tablets to Healthy Postmenopausal Women J. Nutr., November 1, 2009; 139(11): 2037 - 2043. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Setchell, X. Zhao, P. Jha, J. E Heubi, and N. M Brown The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers Am. J. Clinical Nutrition, October 1, 2009; 90(4): 1029 - 1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Messina, S. Watanabe, and K. D. R. Setchell Report on the 8th International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment J. Nutr., April 1, 2009; 139(4): 796S - 802S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Gleason, C. M. Carlsson, J. H. Barnet, S. A. Meade, K. D. R. Setchell, C. S. Atwood, S. C. Johnson, M. L. Ries, and S. Asthana A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women Age Ageing, January 1, 2009; 38(1): 86 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E Rufer, A. Bub, J. Moseneder, P. Winterhalter, M. Sturtz, and S. E Kulling Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: a randomized, double-blind, crossover study Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1314 - 1323. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Brink, V. Coxam, S. Robins, K. Wahala, A. Cassidy, F. Branca, and on behalf of the PHYTOS Investigators Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study Am. J. Clinical Nutrition, March 1, 2008; 87(3): 761 - 770. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A Franke, B. M Halm, L. J Custer, Y. Tatsumura, and S. Hebshi Isoflavones in breastfed infants after mothers consume soy. Am. J. Clinical Nutrition, August 1, 2006; 84(2): 406 - 413. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. R. Setchell and S. J. Cole Method of Defining Equol-Producer Status and Its Frequency among Vegetarians J. Nutr., August 1, 2006; 136(8): 2188 - 2193. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cassidy, J. E. Brown, A. Hawdon, M. S. Faughnan, L. J. King, J. Millward, L. Zimmer-Nechemias, B. Wolfe, and K. D.R. Setchell Factors Affecting the Bioavailability of Soy Isoflavones in Humans after Ingestion of Physiologically Relevant Levels from Different Soy Foods J. Nutr., January 1, 2006; 136(1): 45 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, S. Wang, X. Jia, S. Bajimaya, H. Lin, V. H. Tam, and M. Hu DISPOSITION OF FLAVONOIDS VIA RECYCLING: COMPARISON OF INTESTINAL VERSUS HEPATIC DISPOSITION Drug Metab. Dispos., December 1, 2005; 33(12): 1777 - 1784. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Hedlund, P. D. Maroni, P. G. Ferucci, R. Dayton, S. Barnes, K. Jones, R. Moore, L. G. Ogden, K. Wahala, H. M. Sackett, et al. Long-Term Dietary Habits Affect Soy Isoflavone Metabolism and Accumulation in Prostatic Fluid in Caucasian Men J. Nutr., June 1, 2005; 135(6): 1400 - 1406. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Setchell, C. Clerici, E. D Lephart, S. J Cole, C. Heenan, D. Castellani, B. E Wolfe, L. Nechemias-Zimmer, N. M Brown, T. D Lund, et al. S-Equol, a potent ligand for estrogen receptor {beta}, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora Am. J. Clinical Nutrition, May 1, 2005; 81(5): 1072 - 1079. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Atkinson, C. L. Frankenfeld, and J. W. Lampe Gut Bacterial Metabolism of the Soy Isoflavone Daidzein: Exploring the Relevance to Human Health Experimental Biology and Medicine, March 1, 2005; 230(3): 155 - 170. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Manach, G. Williamson, C. Morand, A. Scalbert, and C. Remesy Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies Am. J. Clinical Nutrition, January 1, 2005; 81(1): 230S - 242S. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wiseman, K. Casey, E. A Bowey, R. Duffy, M. Davies, I. R Rowland, A. S Lloyd, A. Murray, R. Thompson, and D. B Clarke Influence of 10 wk of soy consumption on plasma concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy adults Am. J. Clinical Nutrition, September 1, 2004; 80(3): 692 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A Kroon, M. N Clifford, A. Crozier, A. J Day, J. L Donovan, C. Manach, and G. Williamson How should we assess the effects of exposure to dietary polyphenols in vitro? Am. J. Clinical Nutrition, July 1, 2004; 80(1): 15 - 21. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Manach, A. Scalbert, C. Morand, C. Remesy, and L. Jimenez Polyphenols: food sources and bioavailability Am. J. Clinical Nutrition, May 1, 2004; 79(5): 727 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Cline, A. A. Franke, T. C. Register, D. L. Golden, and M. R. Adams Effects of Dietary Isoflavone Aglycones on the Reproductive Tract of Male and Female Mice Toxicol Pathol, January 1, 2004; 32(1): 91 - 99. [Abstract] [PDF] |
||||
![]() |
A. H. Wu, M. C. Yu, C.-C. Tseng, N. C. Twaddle, and D. R. Doerge Plasma isoflavone levels versus self-reported soy isoflavone levels in Asian-American women in Los Angeles County Carcinogenesis, January 1, 2004; 25(1): 77 - 81. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |